The European Medicines Agency's second ever public hearing under the EU pharmacovigilance legislation – on the long-lasting side-effects of quinolone and fluoroquinolone antibiotics – has drawn a lot of interest from stakeholders who want to share their experiences at the event on June 13.
A total of 115 requests were submitted for participation at the hearing – 55 speakers and 60 observers. Regarding the...




